Lutetium Lu 177 dotatate (Lutathera®) – PRRT

Lutetium Lu 177 dotatate (Lutathera®) – PRRT

Clinical Trials, Technical NETs, Treatment
Short PRRT Primer What is Peptide Receptor Radionuclide Therapy (PRRT)? For those who are still not sure what it's all about.  This is a non-surgical treatment which is normally administered intravenously.  It's based on the use of somatostatin receptors to attract a 'radiopeptide'.  The radiopeptide is a combination of a somatostatin analogue and a radioactive material. As we already know, somatostatin analogues (i.e. Lanreotide/Octreotide) are a NET cell targeting drug, so when combined with radioactivity, it binds with the NET cells and delivers a high dose of targeted radiation to the cancer while preserving healthy tissue in an attempt to reduce or kill tumours.  In general, patients tend to receive up to 4 sessions spaced apart by at least 2 months.  PRRT will not work on all NETs and not…
Read More